Antagonism by domperidone of the ocular hypotensive effect of pergolide

No abstract is available for this paper.

• Publication year

  2006

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF02336684PMID 2379530
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A comparison of the ocular hypotensive effect of 0.025% bromocriptine and 0.25% timolol eye drops in normal human volunteers.

  1989cited by this paper
• The effect of a single oral dose of pergolide on intraocular pressure and pupil diameter.

  1989cited by this paper
• The effects of lisuride, terguride and bromocriptine on intraocular pressure (IOP).

  1989cited by this paper
• Hypotensive Effect of Bromocriptine in Normal Eyes

  1987cited by this paper
• Dopamine and intraocular pressure

  1985cited by this paper
• Stimulation of dopamine receptors (type 2) lowers human intraocular pressure.

  1985cited by this paper
• Bromocriptine eyedrops lower intraocular pressure without affecting prolactin levels.

  1984cited by this paper
• Ocular hypotensive action of ergoline derivatives in rabbits: effects of sympathectomy and domperidone pretreatment.

  1984cited by this paper
• Bromocriptine lowers intraocular pressure without affecting blood pressure.

  1983cited by this paper
• Selective DA2 versus DA1 antagonist activity of domperidone in the periphery.

  1983cited by this paper
• Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part I: Subclassification and functional description.

  1982cited by this paper
• Interaction of pergolide with central dopaminergic receptors.

  1980cited by this paper
• The pharmacological evaluation of pergolide mesylate as a potential anti-parkinson agent.

  1980cited by this paper
• Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity.

  1979cited by this paper
• Effects of (8beta)-8-[methylthio)methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in rats.

  1979cited by this paper
• A NEW TONOMETER SYSTEM

  1973cited by this paper
• A NEW TONOMETER SYSTEM*

  1972cited by this paper

• Role of Dopaminergic Receptors in Glaucomatous Disease Modulation

  2013cites this paper
• Effects of dopamine D-1 and D-2 receptors on intraocular pressure in conscious rabbits

  2005cites this paper
• Fenoldopam, A Selective Dopamine-1 Receptor Agonist, Raises Intraocular Pressure in Males with Normal Intraocular Pressure

  1998cites this paper
• Lisuride Acts at Multiple Sites to Induce Ocular Hypotension and Mydriasis

  1998cites this paper
• Effect of Intravenous Fenoldopam on Intraocular Pressure in Ocular Hypertension

  1997cites this paper
• Topical SDZ GLC-756, a novel dopamine D-1 antagonist and D-2 agonist, lowers intraocular pressure in conscious rabbits.

  1996cites this paper
• The novel dopamine D-1 antagonist and D-2 agonist, SDZ GLC-756, lowers intraocular pressure in healthy human volunteers and in patients with glaucoma.

  1995cites this paper
• Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors.

  1994cites this paper
• Ocular actions of an octahydrobenzo[f]quinoline: Ha117.

  1993cites this paper
• Ocular hypotensive effects of medifoxamine.

  1992cites this paper
• Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans

  1991cites this paper